Jazz Pharmaceuticals JAZZ Repayments of Secured Debt
Repayments of Secured Debt at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RepaymentsOfSecuredDebt.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's repayments of secured debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's repayments of secured debt?
- Jazz Pharmaceuticals (JAZZ) reported repayments of secured debt of $7.8M in Q1 2026.
- How has Jazz Pharmaceuticals's repayments of secured debt changed year-over-year?
- Jazz Pharmaceuticals's repayments of secured debt decreased by 99.0% year-over-year, from $757.8M to $7.8M.
- What is the long-term trend for Jazz Pharmaceuticals's repayments of secured debt?
- Over 2 years (2021 to 2025), Jazz Pharmaceuticals's repayments of secured debt has grown at a -15.8% compound annual growth rate (CAGR), from $1.1B to $781M.
- What does repayments of secured debt mean?
- Cash used to pay off debt backed by assets.
- How do you interpret repayments of secured debt?
- Higher repayments indicate a focus on debt reduction and balance sheet strengthening, which lowers interest expense over time.
- How does repayments of secured debt compare across companies?
- Commonly monitored by credit analysts to assess solvency and financial health.